Committed to reducing CVD-related preventable deaths through advanced biosensing technology.
Committed to reducing CVD-related preventable deaths through advanced biosensing technology.
Headquarters: Belfast, Northern Ireland
Product: HeartKey® ECG/EKG algorithms and analytics
Regulatory: Holds U.S. FDA 510(k) clearances
Employees: ~125
Total disclosed funding: £20.3M (reported)
Cardiac biosensing, ECG signal analytics, digital health and biometric authentication.
2015
Digital health / Medical devices / Biometric security
£3.5M
Reported late-stage seed investment announced July 25, 2017
£4M
Company announcement of a £4M investment round
US$12M
Company announcement of a $12M financing round with participation from existing investors
Latest funding date reported in company snapshot
“Includes UK and Irish venture investors such as Accelerated Digital Ventures (ADV), Kernel Capital, British Business Bank Investments, and First Capital Ventures”